Recent advances in cancer biology reveal that microRNAs (miRNAs) are involved in the regulation of cancer-related genes, or they function as tumor suppressors or oncogenes. In prostate cancer, evidence has accumulated for the contribution of the androgen-dependent gene network to tumor growth, although the precise functions of miRNAs in prostate cancer remain to be investigated. Here, we identified androgen-responsive miRNAs by the short RNA sequencing analysis in LNCaP prostate cancer cells. Among 10 miRNAs with known sequences, we have determined that miR148a reduces the expression of cullin-associated and neddylation-dissociated 1 (CAND1), a negative regulator of SKP1-Cullin1-F-box (SCF) ubiquitin ligases, by binding to the 3 0 -untranslated region of CAND1 mRNA. CAND1 knockdown by small interfering RNA promoted the proliferation of LNCaP cells. Our study indicates the potential contribution of miR-148a to the growth of human prostate cancer.
Introduction
MicroRNAs (miRNAs) are small, non-coding RNAs that regulate gene expression via various mechanisms, such as translational repression, mRNA cleavage, and mRNA degradation. 1 Recent studies have shown that some miRNAs are involved in the pathogenesis of malignancies. 2 More than half of the known miRNAs have been shown to be located in cancer-associated genomic regions or at fragile sites, suggesting that miRNAs contribute to the initiation and progression of human cancers. 3 miRNAs may function as fine-tuners of the cancer-related gene expression, or may themselves function as tumor suppressors or oncogenes. 4 Experimental reports show that the modulation of miRNA expression using miRNA mimics or antagonists can normalize the gene regulatory network and signaling pathways. 5 Thus, miRNAs can be useful as new therapeutic targets in cancer treatment, as well as novel biomarkers in cancer diagnosis and prognosis.
In developed countries, prostate cancer is one of the most common malignancies in men, and has a high rate of mortality. Prostate cancer is initially androgen sensitive, and androgen ablation is one of the therapeutic options at advance stages, although androgen-refractory tumors will survive and lead to fatal disease without effective treatment. 6, 7 Efforts have been made to identify androgen-responsive genes. Our group and others have identified novel androgen target genes that regulate androgen-dependent tumor growth by performing chromatin immunoprecipitation coupled with tiling array (ChIP-chip) analyses. [8] [9] [10] Integrative transcriptome sequencing in prostate cancer cells could detect gene fusions, 11 including known prostate cancer-specific rearrangements TMPRSS2-ERG/ETV1. 12 Recently, miRNA profiling has been reported to be informative and predictive in some malignancies, including prostate cancer. [13] [14] [15] Systematic identification of disease-associated miRNAs will be useful for finding good indicators for prostate cancer management, although a consensus has not been yet achieved in terms of a prostate cancerrelated miRNA signature.
In this study, we identified a set of androgen-induced miRNAs in androgen-sensitive LNCaP prostate cancer cells by performing short RNA sequencing. We showed that miR-148a is a novel androgen-regulated miRNA that promotes cancer cell proliferation. Notably, we found that miR-148a represses the expression of cullin-associated and neddylation-dissociated 1 (CAND1), a negative regulator of SKP1-Cullin1-F-box (SCF) ubiquitin ligases, by binding to the 3 0 -untranslated region (UTR) region of CAND1 mRNA. Our study demonstrates the potential contribution of miR-148a to the progression of human prostate cancer.
Materials and methods

Cell culture
LNCaP cells were purchased from American Type Culture Collection. LNCaP was maintained in RPMI 1640 supplemented with 10% fetal bovine serum. For androgen deprivation, cells were cultured for 3 days in phenol red-free RPMI 1640 with 2.5% dextran-charcoal stripped fetal bovine serum. Vehicle was ethanol.
Short RNA library preparation and sequencing Short RNA library preparation was performed as described. 16 Briefly, purified short RNAs were ligated to chimeric-oligonucleotide adaptors and reverse transcribed to cDNA. The PCR products with 11-40 nt in size were eluted from 12% polyacrylamide gels. The PCR products were digested by a restriction enzyme, concatenated, column purified to eliminate short concatamers and sequenced on the Roche FLX Genome Sequencer. RNAs were aligned to human genome NCBI build 35 and searched for miRNA sequences in miRBase 9.1 database
17
; we approved sequences with a single match in the BLAST best hits. BLAST (blastn) was optimized for short and nearly exact matches with word-size ¼ 7, dust-filter ¼ off and expect-value ¼ 1000.
Quantitative PCR for miRNA
Total RNA was extracted from LNCaP cells using mirVana miRNA Isolation Kit (Applied Biosystems, Foster City, CA, USA) and reverse transcribed to cDNA using TaqMan microRNA reverse transcription kit (Applied Biosystems). Quantitative PCR (qPCR) for cDNA was performed by TaqMan microRNA assay primers using Applied Biosystems 7000 sequence detector. The relative level of miRNA was calculated from the relevant signal by normalization to the signal for U6B small nucleolar RNA.
Transfection of pre-miRs and siRNAs
LNCaP cells were transfected with either miRNA precursors (pre-miRs), control pre-miR, miRNA inhibitors (anti-miR), or control siRNA (siControl, Applied Biosystems) (30 nM each), using SiPort Neo-FX (Applied Biosystems). siRNA-TIP120A (siCAND1, Applied Biosystems) was transfected at a final concentration of 15 nM or 30 nM.
Cell proliferation assay
Pre-miR/siRNA-transfected LNCaP cells (4000 cells per well) were plated in 96-well plates and incubated in RPMI 1640 containing 10% fetal bovine serum. MTS proliferation assay was performed using Cell Titer 96 AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA). Each time point was repeated at least 3 times, in quadruplicate wells at each time point.
qPCR for mRNA Total RNA was reverse transcribed by PrimeScript RT reagent Kit (Takara Biotechnology, Otsu, Shiga, Japan) using random primers. mRNA expression was measured by quantitative reverse-transcription PCR using Applied Biosystems 7000 based on SYBR Green fluorescence. Relative mRNA levels were determined by normalization to glyceraldehyde-3-phosphate dehydrogenase mRNA level. We used the following primers: CAND1 fw:
Western blot analysis
Cell lysates were fractionated on 12.5% SDS-PAGE gels, and transferred onto Immobilon membranes (Millipore, Billerica, MA, USA), which were probed with anti-CAND1 (T36120) (Becton Dickinson, Franklin Lakes, NJ, USA; diluted 1:1000 in TBS-T) or anti-b-actin (A5316) (Sigma, St Louis, MO, USA; diluted 1:1000 in TBS-T) antibodies and visualized with ECL Plus detection system (GE Healthcare, Piscataway, NJ, USA). b-Actin was used as a loading control.
Luciferase vector construction
An 887-bp region of the CAND1 3 0 -UTR including an miR-148a-binding site was amplified from LNCaP cells using the following primers:
wild-type (WT) fw:
0 . The PCR product was cloned into the pGL3-promoter plasmid (Promega). CAND1 deletion mutant 3 0 -UTR lacking the miR-148a-binding site was amplified using the following primers: mutant (mt) fw:
Luciferase assay
LNCaP cells were cotransfected with luciferase vectors using FuGENE6 HD (Roche Applied Science, Penzberg, Upper Bavaria, Germany). Renilla luciferase TK-pRL was cotransfected as a control for transfection efficiency. Luciferase activities were measured 48 h after transfection by Dual Luciferase Assay Kit (Promega). Data represent means ± s.d. from triplicate sets.
Results
Identification of androgen-responsive miRNAs
We performed unbiased sequencing of short RNAs with sizes of 11-40 nt for miRNA fractionation in androgensensitive LNCaP prostate cancer cells treated with R1881 (10 nM). Androgen responsiveness was confirmed in the RNAs from R1881-treated cells (6 and 24 h) compared with that from cells before treatment (0 h), as prototypic androgen targets PSA and TMPRSS2 were upregulated by the treatment. Short RNA libraries were constructed, and 784 315, 512 503, and 470 693 tag sequences were obtained from the libraries for cells treated with R1881
miR-148a promotes prostate cancer cell growth T Murata et al for 0, 6, and 24 h, respectively. Among these by comparing the sequence frequencies between 24 and 0 h, we identified 1809 sequences that were significantly upregulated by androgen. Using the BLAST search, 631 RNA sequences were uniquely mapped to the human genome and 431 sequences were finally defined as androgen-upregulated short RNAs. Among the short RNAs, we focused on the miRNAs with known sequences based on the search by miRBase 9.1. miRNAs in a list of the 10 highest frequencies were selected and the androgen responsiveness (41.5-fold over basal) of the 10 miRNAs was validated by qPCR, using miR-125b as a positive control (Figure 1 ). (Figures 2a and b) . Growth-promoting effects of miR-141, miR-200a, and miR-148a were confirmed by the knockdown experiment with each miRNA inhibitor (anti-miR) (Figures 2c and d) .
miR-148a regulates CAND1 expression in LNCaP cells
Compared with the miR-200 family members including miR-141 and miR-200a, little is known in terms of the physiological relevance of miR-148a. To understand the functions of miR-148a in prostate cancer, we searched potential miR-148a targets using Sanger miRBase Target database. We were particularly interested in a cullinassociated protein CAND1, or TIP120A, as a potential cancer-related target. Cullin is a family of scaffold proteins that are involved in various E3 ubiquitin ligases such as the SCF (ROC1-SKP1-cullin1/Cdc53-F box protein) complex; it has been reported that CAND1 may function as a negative regulator of SCF complex assembly. 19, 20 As cullin-based ubiquitin ligases have important physiological roles such as cell cycle regulation and cell proliferation, we hypothesized that CAND1 expression would be regulated by miR-148a and that this mechanism would facilitate prostate cancer progression. We investigated whether CAND1 mRNA levels would change by transfecting miR-148a precursor in LNCaP cells (Figure 3a) . As expected, miR-148a transfection in LNCaP cells significantly reduced CAND1 expression at mRNA and protein levels, whereas anti-miR-148a upregulated CAND1.
miR-148a directly targets CAND1 by binding to CAND1 3 0 -UTR A highly conserved putative miR-148a-binding site was predicted within the 3 0 -UTR of CAND1 mRNA (Figure 3b ). We generated CAND1 3 0 -UTR luciferase reporter genes containing the miR-148a-binding site (CAND1 WT 3 0 -UTR) or lacking the site (CAND1 mt 3 0 -UTR). CAND1 WT 3 0 -UTR luciferase activity in LNCaP cells was reduced by miR-148a transfection, whereas CAND1 mt 3 0 -UTR activity was not affected. Thus, the in silico identified sequence for miR-148a binding in CAND1 3 0 -UTR was functionally validated as a bona fide miR-148a-binding site.
CAND1 knockdown promotes proliferation of LNCaP cells
Having shown miR-148a to be an androgen-inducible miRNA that directly targets CAND1, we next questioned whether the reduction of CAND1 expression accelerates LNCaP cell growth. Effective knockdown of CAND1 was achieved by a specific siRNA siCAND1 (30 nM), as shown by qPCR and western blot analysis (Figure 4a ). MTS assay showed that the proliferation of LNCaP cells was promoted by siCAND1 compared with control siRNA during the tested period (Figure 4b ).
Discussion
We have for the first time demonstrated that the CAND1 mRNA 3 0 -UTR contains a specific, direct miR-148a target site, and that miR-148a downregulates CAND1 expression at both mRNA and protein levels and promotes proliferative activity in LNCaP cells. Reduction of CAND1 expression has been shown to promote LNCaP cell proliferation. The data suggest that the upregulation of miR-148a could promote prostate cancer growth by reducing its target CAND1. miRNA profiling has been recently performed in various malignancies, including prostate cancer. One of the miRNAs characteristic of prostate cancer is miR125b, 18 which we used as a positive control. miR-125b is upregulated in prostate cancer and confirmed increased expression of one of these targets, EIF4EBP1, in prostate cancer tissues. 21 In terms of the analysis of miR-148a, three microarray data revealed that miR-148a was upregulated in clinical prostate tumors as compared with normal prostate tissues 13 and abundantly expressed in some AR-positive prostate cancer cell lines, such as LAPC4, LNCaP, and VCaP. 13, 22 Our data provide the first evidence that miR-148a exhibits an androgen-inducible miR-148a promotes prostate cancer cell growth T Murata et al expression pattern in LNCaP cells. Besides the hormone responsiveness and the growth-promoting effect in prostate cancer cells, miR-148a has been reported to exert metastasis-inhibitory function in some common types of cancer. 23 It has been recently shown that the overexpression of miR-148a precursor inhibited the growth of androgen-refractory PC3 cells, and even paclitaxel-resistant PC3 cells by repressing an miR-148a target mitogen-and stress-activated protein kinase 1. 24 It is interesting that ectopic miR-148a functions as a tumor suppressor in androgen-refractory PC3 cells, which originally contains a smaller amount of miR-148a than androgen-sensitive LNCaP cells. We consider that miR148a expression would be altered during the progression of cancer stages.
Along with miR-148a, we determined that miR-141 and -200a were androgen-upregulated miRNAs. miR-141 and miR-200a belong to the evolutionarily conserved miR-200 family. 17 The miR-200 family has been shown to determine the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2, 25 and a clinical study reveals that serum levels of miR-141 can be used as a biomaker of prostate cancer. 26 Abundant expression of miR-200a has been also shown in some prostate cancer cell lines.
14 It is notable that measurement of tumor-derived miRNAs in serum or plasma is now possible; the serum level of miR-141 could be a potential diagnostic marker in prostate cancer. 26 Whether miR-148a could also be a useful biomarker in prostate cancer is a subject for future study.
As CAND1 can be donwregulated by miR-148a and CAND1 knockdown can promote LNCaP cell growth, some tumor-specific miRNAs could function as finetuners for the regulation of various protein modification pathways, such as CAND1-associated cullin-neddylation pathways. For instance, one of the cullin proteins, Cul-1, is a scaffold element of SCF complexes that are involved in the proteasomal degradation of numerous proteins that regulate cell cycle progression. Aberrant expression of the SCF components is considered to have a role during tumourigenesis. In high-grade neuroendocrine lung tumors, neddylated forms of Cul-1 are miR-148a promotes prostate cancer cell growth T Murata et al specifically expressed and are associated with downregulation of the Cul-1 inhibitor CAND1 and a high level of cyclin E. 27 The present results of miRNA inhibitor experiments indicate that miR-148a as well as the miR-200 family will be useful as new therapeutic targets in prostate cancer. Each miRNA binds to various genes and modulates the expression of their targets, so the determination of distinct miRNA targets will be important before miRNA inhibitors are applied in clinical practice.
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